Phase 3 randomized trials have shown that maintenance rituximab ( MR ) therapy or radioimmunotherapy ( RIT ) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma ( FL ) , but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework .